OAM
ACRS icon

Oxford Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Oxford Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,351
Closed -$69.1K – 478
2025
Q3 		$69.1K Buy
+36,351
New +$63.4K 0.02% 419
2025
Q2 		– Sell
-41,723
Closed -$63.8K – 512
2025
Q1 		$63.8K Buy
+41,723
New +$89K 0.03% 447
2020
Q1 		– Sell
-27,599
Closed -$52K – 224
2019
Q4 		$52K Buy
+27,599
New +$45.7K ﹤0.01% 1664
2019
Q2 		– Sell
-35,230
Closed -$211K – 1669
2019
Q1 		$211K Buy
35,230
+12,072
+52% +$80K ﹤0.01% 1497
2018
Q4 		$171K Buy
+23,158
New +$239K ﹤0.01% 1572
2017
Q1 		– Sell
-38,781
Closed -$1.05M – 1386
2016
Q4 		$1.05M Buy
+38,781
New +$989K 0.04% 465

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Oxford Asset Management's ACRS Position: Q4 2025 in Review

Oxford Asset Management sold out of Aclaris Therapeutics (ACRS) in Q4 2025, closing a stake of 36,351 shares — an estimated $69.1K sold.

Oxford Asset Management first reported a position in ACRS in Q4 2016 and held it in 6 quarters. The position peaked at $1.05M in Q4 2016. 122 funds tracked by Wall St. Rank hold ACRS as of Q4 2025.

  • Oxford Asset Management reported no remaining Aclaris Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Oxford Asset Management sold 36,351 Aclaris Therapeutics shares in Q4 2025, an estimated $69.1K.
  • Oxford Asset Management first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 6 quarters.
  • Oxford Asset Management's Aclaris Therapeutics position peaked at $1.05M in Q4 2016.
  • 122 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.